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Abstract
Background: In patients with HIV and tuberculosis (TB) in resource-constrained settings, smear-negative disease has been
associated with higher mortality than smear-positive disease. Higher reported mortality may be due to misdiagnosis,
diagnostic delays, or because smear-negative disease indicates more advanced immune suppression.
Methods: We analyzed culture-confirmed, pulmonary TB among patients with TB and HIV in the United States from 1993–
2008 to calculate prevalence ratios (PRs) for smear-negative disease by demographic and clinical characteristics. Allowing
two years for treatment outcome to be reported, we determined hazard ratios (HRs) for survival by smear status, adjusted
for significant covariates on patients before 2006.
Results: Among 16,710 cases with sputum smear results, 6,739 (39%) were sputum smear-negative and 9,971 (58%) were
sputum smear-positive. The prevalence of smear-negative disease was lower in male patients (PR: 0.89, 95% confidence
interval [CI]: 0.86–0.93) and in those who were homeless (PR: 0.92, CI: 0.87–0.97) or used alcohol excessively (PR: 0.91, CI:
0.87–0.95), and higher in persons diagnosed while incarcerated (PR: 1.20, CI: 1.13–1.27). Patients with smear-negative
disease had better survival compared to patients with smear-positive disease, both before (HR: 0.82, CI: 0.75–0.90) and after
(HR: 0.81, CI: 0.71–0.92) the introduction of combination anti-retroviral therapy.
Conclusions: In the United States, smear-negative pulmonary TB in patients with HIV was not associated with higher
mortality, in contrast to what has been documented in high TB burden settings. Smear-negative TB can be routinely and
definitively diagnosed in the United States, whereas high-burden countries often rely solely on AFB-smear microscopy. This
difference could contribute to diagnostic and treatment delays in high-burden countries, possibly resulting in higher
mortality.
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Introduction
Sputum smear examination of acid-fast bacilli (AFB) is the
cornerstone of tuberculosis (TB) diagnosis worldwide. Before the
HIV epidemic, AFB smear-negative TB was diagnosed in a
smaller proportion of TB patients than it is today and was
regarded as earlier or less severe disease [1]. Patients diagnosed
with smear-negative TB are less infectious and, prior to the HIV
epidemic, had lower morbidity and mortality than smear-positive
TB [2–5]; for these reasons, smear-negative TB disease has been a
lower priority for TB control efforts. In resource-limited countries,
however, the proportion of pulmonary TB disease that is smear-
negative has increased over the past two decades, a shift largely
attributed to the growing HIV epidemic [6,7]. Moreover, in
countries with a high prevalence of HIV, patients diagnosed with
smear-negative TB have been shown to have higher mortality than
patients with smear-positive TB [8–12], raising new questions and
concerns about this form of TB disease.
A number of explanations for the increased mortality associated
with smear-negative TB in resource-limited, high HIV prevalence
countries have been proposed. Some researchers suggest that
smear-negative disease in HIV-infected patients may indicate
more advanced immune suppression, which may be mediating the
observed differences in survival [1,8–10]. Laboratory confirmation
is rarely performed in countries with high HIV prevalence, and
others conjecture that diagnostic inaccuracy and incorrect therapy
are important reasons for the high mortality [8,11,12]. In addition,
practical difficulties diagnosing smear-negative TB – such as the
need for additional smears, chest radiographs, or trials of
antibiotics – lead to delays in appropriate treatment, which have
been clearly associated with poor outcomes [13–15]. Finally, some
countries did not always include rifampicin in the continuation
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phase for smear-negative disease, which may explain the observed
higher mortality in patients with HIV infection [8].
Analyses of the association between sputum AFB smear result
and mortality in patients with HIV and TB that assess these
hypotheses would be helpful in designing interventions to improve
outcomes. In the United States, TB is diagnosed by means of
extensive laboratory testing, which includes microscopy, nucleic
acid amplification and specimen culture [16]. The widespread use
of testing to confirm pulmonary TB, along with a well-established
national TB surveillance system with over 15 years of data,
provide a unique opportunity to investigate the association
between AFB smear result and treatment outcomes in the United
States. Additionally, because the diagnostic process is different in
the United States than in resource-limited settings, comparing
mortality of smear-negative TB patients between these two settings
may help refine hypotheses for the observed increase in mortality
seen in resource-limited settings. We used the U.S. National TB
Surveillance System (NTSS) to investigate clinical features
associated with AFB smear status in TB patients infected with
HIV and analyzed the effect of AFB smear status on survival.
Methods
Ethical Considerations
Data were collected and analyzed as part of routine public
health surveillance and not human subjects research, and therefore
institutional review board approval was not required.
Study Population
In the United States since 1993, all states and affiliated
jurisdictions have reported incident cases of TB to the Centers
for Disease Control and Prevention (CDC) using a standardized
case report form, the Report of Verified Case of Tuberculosis
(RVCT) [17]. The RVCT includes socio-demographic, laborato-
ry, and clinical information on TB patients as well as follow-up
data on TB treatment outcomes. These data have been captured
as well-defined variables [18].
We restricted our analysis to persons with positive HIV infection
status reported on the RVCT, and included all sputum culture-
confirmed cases of pulmonary TB, including those with both
pulmonary and extrapulmonary involvement, that were reported
by the District of Columbia and 48 of the 50 states. California did
not report HIV status directly to the NTSS; HIV status of TB
patients from California was determined by matching patients on
the state-level TB and AIDS registries. HIV was missing for all
California TB patients not matched to the state AIDS registry
prior to 2005 and for all California TB cases from 2005–2008.
Given the difference in reporting and potential for bias, we
excluded TB patients from California from our analyses, and
conducted separate analyses of California TB/AIDS patient
mortality data. Additionally, Vermont stopped reporting HIV
data to the CDC in 2006; because there were fewer than five
Vermont patients with TB/HIV infection over the entire study
period, we excluded patients from Vermont from analyses without
examining state-specific mortality results.
For demographic and clinical analyses of cross-sectional data,
we included all patients with a known smear status who were
reported to the NTSS from January 1, 1993 until December 31,
2008. For survival analyses, we included only patients who were
documented to be alive at diagnosis, initiated anti-TB therapy, and
were reported to the CDC as a culture-confirmed case through
December 31, 2006, to allow two years for reporting of TB
treatment outcomes.
In order to account for the population effect of highly active
anti-retroviral therapy (HAART) on survival, we conducted
separate analyses for the time periods from 1993 to 1997, before
HAART became widely available, and from 1998 to 2006, when
patients with TB and HIV were routinely prescribed HAART.
There are no NTSS data collected about CD4 count, HIV viral
load, or anti-retroviral use, so we were unable to assess the effect of
these variables in our analysis.
AFB Smear Definitions
A TB patient was sputum smear-positive if any result of a
microscopic examination of a sputum smear (expectorated or
induced) was positive for acid-fast bacilli (AFB). This excludes
pulmonary secretions obtained by tracheal aspirations, bronchos-
copy procedures, or gastric aspiration. Sputum smear positivity
grade is not available in the NTSS. A TB patient was sputum
smear-negative if all results of microscopic examination of sputum
smears were negative for AFB. As recommended, at least three
samples of sputum are generally sent for microscopy in the United
States [19].
Statistical Analyses
To investigate features associated with AFB smear status, we
compared frequency distributions of smear-negative TB with
smear-positive disease across categorical demographic and clinical
variables (gender, age group, race/ethnicity, nationality [defined
as U.S.- or foreign-born], correctional facility at diagnosis,
homelessness, excess alcohol use, injection drug use, previous TB
diagnosis, tuberculin skin test [TST] result, and chest radiograph
result), defined in the RVCT [18]. Associations are presented as
prevalence ratios (PRs) along with 95% confidence intervals (CIs).
Prevalence ratios can be interpreted as the proportion (or
prevalence) of smear-negative disease among patients with a
specific characteristic (e.g., male gender), divided by the propor-
tion of smear-negative disease in a pre-determined reference group
(e.g., female gender).
To assess potential treatment delays by AFB smear status, we
compared the median time from collection date of the first sputum
that grew Mycobacterium tuberculosis to the start date of TB therapy
between smear-negative and smear-positive cases using a Wil-
coxon two-sample test. The RVCT records the date that initial
sputum was collected only for cases that had documented
conversion from a positive to a negative culture. We were not
able to analyze survival of patients who died before diagnosis was
made because neither date of symptom onset nor reason for
evaluation for TB disease are reported in the RVCT.
To investigate the relationship between AFB smear status and
survival during TB treatment, we performed comparative survival
analyses by smear status based on time from start of TB therapy to
death (as a TB treatment outcome). To ensure uniform follow-up
for treatment outcomes of all patients, we censored patients at 730
days and didn’t capture specific treatment outcomes if they were
recorded more than two years after the start of therapy. Patients
with outcomes other than death were censored based on either
date of stopping TB therapy or last known follow-up. Overall
survival distributions for both groups were estimated using the
Kaplan-Meier method and compared via log-rank test statistics.
We fit a Cox multivariable proportional hazards model after
testing the proportional hazards assumption for each variable. We
identified demographic and behavioral variables that were either
epidemiologically relevant, or were significantly associated with
mortality in bivariate analysis (p,0.01) and adjusted for them;
these variables included age group, race, nationality, incarceration
at diagnosis, previous TB, as well as reported injection drug use
Smear Negative TB/HIV Patients’ Survival
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(IDU), excessive alcohol use, and homelessness in the past year.
We assessed variables for effect modification and, given the large
sample size, dropped from the model all variables that did not
meet a significance level of p,0.01. All statistical analyses were
performed using SAS, version 9.2 (Cary, NC).
Results
Case Estimates and Trends
From 1993 through 2008, there were 17,089 culture-confirmed
patients with pulmonary TB and HIV infection, 16,710 of whom
had a sputum smear result reported. Of those, 6,739 (40%) were
sputum smear-negative and 9,971 (60%) were sputum smear-
positive. The annual proportion of TB cases that were smear-
negative varied from 36% to 45%; however, there was no
apparent linear trend (Figure 1).
Associated Characteristics of Smear-Negative TB
Of the 6,739 patients with HIV infection and smear-negative
TB, the majority were male (n = 4,922 or 73%), black (n = 4,574 or
68%), aged 25–44 (n = 4,570 or 68%) and U.S.-born (n = 5,149 or
77%) (Table 1). Smear-negative TB was more prevalent among
persons in correctional facilities at the time of TB diagnosis (PR:
1.20, CI: 1.13–1.27) and less prevalent among patients who were
homeless (PR: 0.92, CI: 0.87–0.97) (Table 1). The prevalence of
smear-negative disease was lower among those who used alcohol
excessively compared to those who did not (PR: 0.91, CI: 0.87–
0.95), but did not differ among patients by injection drug use or
history of previous TB diagnosis (Table 2).
Time to Initiation of Therapy
Among patients who were alive at diagnosis and had available
date of initial sputum collection, the median number of days
between the collection of the first sputum specimen that grew M.
tuberculosis to the start date of therapy was 1 (75th percentile = 5,
25th percentile = 0; IQR = 5) for the 6,698 smear-positive patients
and 12 (75th percentile = 35, 25th percentile = 0; IQR = 35) for the
4,342 smear-negative patients, indicating a significant delay in
treatment initiation (p,0.0001).
Survival Analyses
Patients with HIV and smear-negative TB had significantly
better survival during TB treatment than patients with HIV and
smear-positive TB (log rank statistic = 36.1, p,0.0001) (Figure 2).
This difference persisted in sub-group analysis of TB/HIV patients
diagnosed before the widespread use of HAART (1993–1997) (log
rank statistic = 22.7, p,0.0001) and after HAART became widely
available (1998–2006) (log rank statistic = 10.9, p = 0.0009).
In the multivariate Cox proportional hazards model, smear-
negative TB/HIV patients had a 19% lower risk of death during
TB treatment, even after adjusting for gender, age group, race/
ethnicity, nationality, correctional institution residence at time of
diagnosis, IDU, and alcohol; the hazard ratio was similar for TB/
HIV patients diagnosed from 1993–1997 and for patients
diagnosed from 1998–2006 (Table 3). When we conducted
separate analysis of California TB patients who matched to their
state AIDS registry, patients with smear-negative TB had an even
lower risk for death than patients with smear-positive disease (adj
HR 0.67, CI: 0.53–0.84 for patients diagnosed from 1993–1997;
adj HR 0.79, CI: 0.49–1.28 for patients diagnosed from 1998–
2006).
Discussion
Our data demonstrate that, among U.S. patients with HIV,
smear-negative TB patients who initiated treatment had signifi-
cantly lower 2-year mortality than smear-positive patients. This
was true even in the pre–HAART era, when mortality from HIV/
AIDS was exceedingly high. The strengths of this study include the
robustness of this population-based data, which has been estimated
as .99% complete for capturing TB cases [20], the routine use of
culture in the United States to confirm TB and the use of other
diagnostic tests to identify opportunistic pulmonary infections
other than TB.
Figure 1. Sputum smear status among patients with HIV and culture-confirmed TB among those with reported sputum smear,
United States, 1993–2008. Black bars indicate the percentage of patients with reported sputum smear result who were smear-positive. Gray bars
indicate the percentage of patients with who were smear-negative.
doi:10.1371/journal.pone.0047855.g001
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The finding of lower mortality in patients with HIV treated for
smear-negative TB in the United States is different from what has
been reported in resource-limited settings [8–10,21–23]. The
significantly decreased hazard for death among smear-negative
TB/HIV patients in our analysis suggests that those with smear-
negative TB who were alive at the time diagnosis was established,
overall, had earlier, less severe disease than patients with smear-
positive TB.
Many studies have demonstrated that patients with HIV
infection have higher rates of smear-negative TB [24–26], but it
is unclear if this is due to screening, or misdiagnosis, or if
immune suppression itself diminishes the bacillary density in
sputum. In the United States, incarcerated persons usually
undergo aggressive TB screening [27], and the increased
prevalence of smear-negative disease among this population
supports the effect of screening in identifying early stage disease.
This, along with the higher prevalence of smear-negative disease
in TB patients who have normal chest radiographs seen in this
analysis, suggests that smear-negative disease may indeed be an
early stage of TB in the United States, even among patients
with HIV.
Smear status may correlate with degree of immune dysfunc-
tion, and it has been hypothesized that, because worsening
immune suppression impairs pulmonary cavitation [28,29] and
cavitation correlates with smear-positivity [30], patients with
HIV and TB who are smear-negative have more severe
immune suppression [1,6]. There is, however, little consistency
among studies that have directly investigated the correlation
between immune function, as measured by CD4 count, and
smear status. Some studies have shown that sputum bacillary
density appears to decrease with falling CD4 count [31,32], but
other studies have demonstrated that the more severely immune







Prevalence Ratio of Smear-Negative
Disease (95% Conf. Int.)
Total 6,739 9,971
Gender
Male 4,922 (39) 7,642 (61) 0.89 (0.86–0.93)
Female 1,817 (44) 2,329 (56) Referent
Age in years{
0–14 17 (53) 15 (47) 1.32 (0.95–1.82)
15–24 192 (39) 296 (61) 0.97 (0.87–1.09)
25–44 4,569 (40) 6,750 (60) Referent
45–64 1,846 (40) 2,723 (60) 1.00 (0.96–1.04)
65+ 114 (38) 187 (62) 0.94 (0.81–1.09)
Race/ethnicity1
Hispanic 1,260 (39) 2,010 (61) 0.95 (0.88–1.01)
American Indian/Alaska Native 16 (33) 32 (67) 0.82 (0.55–1.23)
Asian 89 (36) 161 (64) 0.87 (0.73–1.04)
Black or African-American 4,574 (41) 6,599 (59) 1.01 (0.95–1.07)
Native Hawaiian/Pacific Islander 0 (0) 4 (100) n/a
White 776 (41) 1,131 (59) Referent
Nationality
U.S.-born 5,148 (40) 7,623 (60) Referent
Foreign-born 1,553 (40) 2,297 (60) 1.00 (0.96–1.05)
Unknown 38 (43) 51 (57) 1.06 (0.83–1.35)
Correctional facility resident (at time of TB diagnosis)**
Yes 627 (48) 688 (52) 1.20 (1.13–1.27)
No 5,876 (40) 8,893 (60) Referent
Unknown/Missing 104 (36) 188 (64) 0.90 (0.77–1.05)
Homeless (within past year)**
Yes 883 (37) 1,489 (63) 0.92 (0.87–0.97)
No 4,901 (41) 7,144 (59) Referent
Unknown/Missing 823 (42) 1,136 (58) 1.03 (0.98–1.09)
*Percentages are the proportion with a specific smear status among all patients with the characteristic who had a known smear status.
{One smear-negative case had an unknown age and is not included.
1There were 6 smear-positive cases and 2 smear-negative cases designated as multiple race and 28 smear-positive and 22 smear-negative cases designated as unknown
race, these were not included.
**Among patients aged 15–64 (6,607 smear-negative, 9,769 smear-positive).
doi:10.1371/journal.pone.0047855.t001
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compromised patients seem to have higher rates of smear-
positive TB disease [33–36]. The discrepant findings suggest
that the correlation between immune functioning and sputum
bacillary density may not be linear. While we were unable to
directly account for immune suppression in our analysis, our
findings do not support the hypothesis that among patients with
HIV, smear-negative TB disease is associated with greater
immune suppression than smear-positive TB disease.
Differences in the study populations themselves may also
explain why our findings differ from those previously published
from resource-limited settings with higher HIV prevalence. By
including only TB cases with microbiologic confirmation of
disease, we eliminated non-TB pulmonary diseases (e.g., Pneumo-
cystis jirovecii pneumonia, fungal diseases, etc.,) that otherwise might
be misdiagnosed as TB. In countries that are unable to perform
routine sputum cultures, the diagnosis of pulmonary TB in a
patient with negative sputum smears is based on clinical and
radiologic findings. These findings, however, are often nonspecific
in persons with HIV, especially those with smear-negative disease
[26,37]. In our results, for example, 1,051 (16%) of 6,481 smear-
negative, culture-confirmed pulmonary TB patients with chest
radiograph reports had films that were interpreted as normal. In
studies that did not use culture as a gold standard, it is likely that a
substantial proportion of smear-negative TB patients was misdi-
agnosed and inappropriately treated, thus leading to higher
mortality.
It is probable that patients with smear-negative TB in
resource-limited countries have even more considerable diag-
nostic and treatment delays than smear-negative TB/HIV
patients in the United States. Because smear microscopy is
frequently the sole diagnostic laboratory test available, sputum
examinations are usually repeated multiple times for TB patients
whose initial sputum smears are negative for AFB, causing
significant delays in diagnosis and treatment [13,14]. Indeed,
current international guidelines suggest that, in the absence of
mycobacterial culture, a minimum of at least two sputum
specimens negative for AFB, radiographic abnormalities consis-
tent with active TB, laboratory confirmation of HIV infection
or strong clinical evidence of HIV infection, and a decision by a
clinician to treat with anti-TB medications should be docu-
mented to categorize a patient as a smear-negative TB case
[38]. These delays have deleterious consequences for both the
individual and public health [15,39]. Delays in TB diagnosis
among patients with HIV are particularly dangerous for the
individual since HIV infection in patients with TB, regardless of
smear status, is associated with high early mortality [7,40]. In
our analysis, time to initiation of therapy was significantly
longer for surviving patients with smear-negative TB than for
patients with smear-positive disease. These diagnostic and
treatment delays, and their effect on survival, are likely to be
smaller in the United States, where ancillary studies (such as
sputum culture and nucleic acid amplification) are often
Table 2. Behavioral and Clinical Characteristics of Patients with HIV-Infection and Culture-Confirmed Pulmonary TB, by Sputum






Prevalence Ratio of Smear-
Negative Disease
(95% Conf. Int.)
Excess alcohol use (within past year){
Yes 1,410 (38) 2,329 (62) 0.91 (0.87–0.95)
No 3,936 (41) 5,563 (59) Referent
Unknown/Missing 1,255 (40) 1,877 (60) 0.97 (0.92–1.02)
Injection drug use (within past year){
Yes 804 (41) 1,155 (59) 1.01 (0.96–1.07)
No 4,548 (40) 6,685 (60) Referent
Unknown/Missing 1,255 (39) 1,929 (61) 0.97 (0.93–1.02)
Previous TB diagnosis1
Yes 321 (38) 523 (62) 0.94 (0.86–1.03)
No 6,358 (40) 9,361 (60) Referent
Unknown/Missing 60 (41) 87 (59) 1.01 (0.83–1.23)
Tuberculin skin test (TST) result1
Positive 2,467 (46) 2,911 (54) Referent
Negative 1,537 (38) 2,539 (62) 0.82 (0.78–0.86)
Unknown 2,735 (38) 4,521 (62) 0.82 (0.79–0.86)
Chest Radiograph**
Normal 1,051 (60) 707 (40) 1.62 (1.55–1.70)
Abnormal – consistent with TB 4,881 (36) 8,375 (64) Referent
Abnormal – not consistent with TB 287 (55) 237 (45) 1.49 (1.37–1.61)
Abnormal – unknown result 262 (42) 366 (58) 1.13 (1.03–1.25)
*Percentages are the proportion with a specific smear status among all patients with the characteristic who had a known smear status.
{Among patients aged 15–64 (6,607 smear-negative, 9,769 smear-positive).
1Among all patients (6,739 smear-negative, 9,971 smear-positive).
**Among patients with a reported chest radiograph result (6,481 smear-negative, 9,685 smear-positive).
doi:10.1371/journal.pone.0047855.t002
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submitted at the same time that smears are collected, than in
countries where ancillary tests may not be readily available
[39,41].
Finally, it is also possible that differences in treatment
contributed to the different findings. In some resource-limited
countries, patients with smear-negative TB were not always
treated with rifampicin throughout their treatment regimens [1].
Moreover rifampicin, because of its spectrum of activity, may treat
some infections other than TB [7,42]. The RVCT does not collect
TB case management details, so we were not able to examine the
effect of changes in TB treatment, or adherence to treatment, over
time.
This study must be interpreted with the following consider-
ations. Fluorescent microscopy has been increasingly used in the
United States over the time period studied, and it is more
sensitive for detection than microscopy used in most high TB
burden settings [43]. Thus, findings from smear-negative TB
patients in this study may differ from those among patients
designated as sputum smear-negative based on less sensitive
microscopy methods. A difference in the sensitivity of diagnostic
technique, however, might explain a change in the size of the
hazard rate between smear-negative TB and smear-positive TB,
but would not account for a reversal. We were not able to
examine patient-level effects of HAART since HIV treatment
data is not reported on the RVCT; yet ecologic analyses did
not suggest differences in the relationship between smear-
negative TB disease and mortality in the pre- and post-HAART
data. Importantly, we were unable to include patients who died
before diagnosis was established, so we cannot make conclusions
about all persons with smear-negative TB disease, and these
findings are directly relevant only to patients who are alive at
diagnosis and initiate therapy.
Figure 2. Survival Curves for patients with HIV-infection and culture-confirmed pulmonary TB, by sputum smear result, United
States, 1993–2006. Solid line indicates the Kaplan-Meier survival curve for smear-positive patients. Dotted line indicates the Kaplan-Meier survival
curve for smear-negative patients.
doi:10.1371/journal.pone.0047855.g002
Table 3. Hazard Ratios for Death among Patients with HIV-
infection and Culture-Confirmed Pulmonary TB Alive at








Smear-positive 2,212 (27) 6,107 (73) Referent
Smear-negative 1,112 (22) 4,053 (78) 0.81 (0.76–0.88)
HIV-infected, 1993–1997
Smear-positive 1,527 (33) 3,072 (67) Referent
Smear-negative 756 (27) 2,026 (73) 0.82 (0.75–0.90)
HIV-infected, 1998–2006
Smear-positive 685 (18) 3,035 (82) Referent
Smear-negative 356 (15) 2,027 (85) 0.81 (0.71–0.92)
*Excluding patients reported after 2006 (536 smear-positive, 431 smear-
negative), not documented as alive at diagnosis (191 smear-positive, 362 smear-
negative), with no documented treatment (35 smear-positive, 112 smear-
negative), or whose recorded outcome date preceded start of therapy or was
missing (153 smear-positive, 110 smear-negative).
{Other outcomes not represented as a column in this table include patients
who moved during treatment or were lost (650 smear-positive, 484 smear-
negative), were uncooperative with therapy (52 smear-positive, 45 smear-
negative), or whose outcomes were otherwise not known (35 smear-positive,
30 smear-negative),
1Adjusted for gender, age group, race/ethnicity, nationality, incarceration,
alcohol and drug use, and previous TB; after adjustment, homelessness in the
previous year was the only examined covariate that was no longer statistically
significant.
doi:10.1371/journal.pone.0047855.t003
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In the United States, mortality in patients with HIV infection
was not higher among patients with smear-negative TB disease,
as compared to those with smear-positive disease, and it is
reasonable to conclude that smear-negative TB in patients who
initiate treatment appears to represent an earlier or less severe
form of TB disease. The difference between these findings and
those from resource-limited settings is likely because diagnostics
are better in this resource-rich setting. Accurate and timely TB
diagnosis remains of paramount importance worldwide, espe-
cially as the global HIV epidemic confounds clinical presenta-
tion and worsens disease outcomes, and the findings of this
analysis argue for the need for improved, affordable diagnostic
tests in high-burden, resource-limited countries. In addition,
greater efforts to identify TB cases early through active
screening in high-risk groups are critical and must be combined
with improved outreach to persons with limited healthcare
access.
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